세계의 PEG화 의약품 시장(-2035년) : 분자별(고분자 의약품, 저분자 의약품, 지질 나노입자 및 리포솜), 용도별, 유통 경로별, 지역별

Global PEGylated Drugs Market Research Report Information by Molecule (Macromolecular Drugs, Small Molecular Drugs and Lipid Nanoparticles (LNP) and Liposomes), by Application (Oncology, Neurology, Autoimmune Diseases, Haematology and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) Forecast till 2035

Market Overview

The PEGylated Drugs Market is expected to grow at a substantial CAGR of 5.17% during the review period. Pegylation is the process of binding covalent and non-covalent glycol polymer chains to bioactive molecules such as peptides, proteins, antibody fragments, enzymes, and oligonucleotides. It is a safe strategy for improving the therapeutic efficacy of drugs in a clinical environment. There are various FDA-approved pegylated medicines used in therapeutic settings.

The growing prevalence of chronic diseases, advances in biologics, and newly approved pegylated pharmaceuticals are driving the worldwide pegylated market. Furthermore, high production costs, regulatory barriers, and potential adverse effects are limiting considerations for the market. However, expanding markets, novel medication delivery technologies, and customized medicine will give future market growth prospects.

The research includes a full overview of the pegylated antibody's benefits, market growth, driving forces, and challenges. It also sheds information on the leading key players' contributions and developments in the PEGylated Proteins Market.

The primary driving force behind the growth of the PEGylated Drugs Market is the rising prevalence of diseases such as cancer, the advancement of biologics sectors, and the expansion of pharmaceutical businesses worldwide. Furthermore, the rising incidence of chronic illnesses and cancer-related deaths in Canada will contribute to the expansion of pegylated pharmaceuticals in the market.

Market Segment Overview

The PEGylated Drugs Market is divided into three segments: molecule, indication, and region.

The Market is divided into three segments based on molecule: macromolecular drugs, small molecular drugs, and lipid nanoparticles (LNP) and liposomes.

The global pegylated pharmaceuticals market is divided into five applications: oncology, neurology, autoimmune diseases, haematology, and others.

The market is divided into three segments based on distribution channel: hospital pharmacies, retail pharmacies, and online pharmacies.

Regional analysis

The Global PEGylated Drugs Market has been classified by region: North America, Europe, Asia-Pacific, and the Rest of the World. North America held the greatest market share in 2024 and is expected to reach USD 8,969.41 million by 2035. However, Asia-Pacific is expected to develop at the fastest CAGR of 7.03% over the projection period.

The American market is separated into two regions: North and South America. The United States and Canada are the dominant regions in the North American market. The increased prevalence of chronic diseases, such as cancer, is driving market expansion.

The European government's assistance and investment in lowering chronic diseases is fueling the expansion of the regional market. The European continent is further divided into Western Europe and Eastern Europe. Western Europe is also divided into the United Kingdom, Italy, France, Spain, and the rest of Western Europe.

Major players.

Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Biogen, BioMarin Pharmaceutical Inc, Coherus BioSciences, Enzon, and Leadiant Biosciences, Inc. are among the companies operating in the PEGylated Drugs Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TYPE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES
  • 4.2.2 ADVANCEMENTS IN BIOLOGICS
  • 4.2.3 RECENTLY APPROVED PEGYLATED DRUGS
• 4.3 RESTRAINTS
  • 4.3.1 HIGH PRODUCTION COSTS
  • 4.3.2 REGULATORY HURDLES
  • 4.3.3 POTENTIAL SIDE EFFECTS
• 4.4 OPPORTUNITY
  • 4.4.1 EMERGING MARKETS
  • 4.4.2 INNOVATIVE DRUG DELIVERY SYSTEMS
  • 4.4.3 PERSONALIZED MEDICINE

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 IMPACT OF COVID-19 ON THE GLOBAL PEGYLATED DRUGS MARKET
• 5.3 QUALITATIVE ANALYSIS ON ANTI-PEG ANTIBODIES AND IMPACT ON PEGYLATED DRUGS 50

6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE

• 6.1 OVERVIEW
• 6.2 MACROMOLECULAR DRUGS
  • 6.2.1 PROTEIN AND PEPTIDE
  • 6.2.2 ENZYME
  • 6.2.3 APTAMER
• 6.3 SMALL MOLECULAR DRUGS
• 6.4 LIPID NANOPARTICLES (LNP) AND LIPOSOMES

7 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 ONCOLOGY
• 7.3 NEUROLOGY
• 7.4 AUTOIMMUNE DISEASES
• 7.5 HAEMATOLOGY
• 7.6 OTHERS

8 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CAHNNEL

• 8.1 OVERVIEW
• 8.2 HOSPITAL PHARMACY
• 8.3 ONLINE PHARMACY
• 8.4 RETAIL PHARMACY

9 GLOBAL PEGYLATED DRUGS MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 AUSTRALIA
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST & AFRICA
  • 9.5.2 SOUTH AMERICA
    • 9.5.2.1 BRAZIL
    • 9.5.2.2 MEXICO
    • 9.5.2.3 ARGENTINA
    • 9.5.2.4 REST OF SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 MARKET SHARE ANALYSIS, 2024
• 10.3 COMPETITOR DASHBOARD
• 10.4 PUBLIC PLAYERS STOCK SUMMARY
• 10.5 CMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT APPROVAL
  • 10.6.2 PRODUCT EXPANSION
  • 10.6.3 APPROVAL DENIED
  • 10.6.4 PRODUCT DISCONTINUATION
  • 10.6.5 AGREEMENT/ACQUISITION
  • 10.6.6 CLINICAL TRIAL FINDINGS

11 COMPANY PROFILES

• 11.1 AMGEN INC.
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 PFIZER INC.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 BIOGEN
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 KEY STRATEGIES
• 11.4 BAYER AG
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGY
• 11.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCT OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 KEY STRATEGIES
• 11.6 NOVO NORDISK A/S
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 KEY STRATEGIES
• 11.7 SANDOZ GROUP AG
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 KEY STRATEGIES
• 11.8 ASTRAZENECA
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 KEY STRATEGIES
• 11.9 COHERUS BIOSCIENCES, INC.
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 F. HOFFMANN-LA ROCHE LTD.
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 SWOT ANALYSIS
  • 11.10.6 KEY STRATEGIES
• 11.11 JOHNSON & JOHNSON INC.
  • 11.11.1 COMPANY OVERVIEW
  • 11.11.2 FINANCIAL OVERVIEW
  • 11.11.3 PRODUCTS OFFERED
  • 11.11.4 KEY DEVELOPMENTS
  • 11.11.5 SWOT ANALYSIS
  • 11.11.6 KEY STRATEGIES
• 11.12 ALNYLAM PHARMACEUTICALS, INC.
  • 11.12.1 COMPANY OVERVIEW
  • 11.12.2 FINANCIAL OVERVIEW
  • 11.12.3 PRODUCTS OFFERED
  • 11.12.4 KEY DEVELOPMENTS
  • 11.12.5 KEY STRATEGIES
• 11.13 LES LABORATOIRES SERVIER
  • 11.13.1 COMPANY OVERVIEW
  • 11.13.2 FINANCIAL OVERVIEW
  • 11.13.3 PRODUCT OFFERED
  • 11.13.4 KEY DEVELOPMENTS
  • 11.13.5 KEY STRATEGIES

12 DATA CITATIONS